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AbstrAct
Introduction Phase I of the Cancer Research UK Stratified 
Medicine Programme (SMP1) was designed to roll out 
molecular pathology testing nationwide at the point of 
cancer diagnosis, as well as facilitate an infrastructure 
where surplus cancer tissue could be used for research. It 
offered a non-trial setting to examine common UK cancer 
genetics in a real-world context.
Methods A total of 26 sites in England, Wales and 
Scotland, recruited samples from 7814 patients for genetic 
examination between 2011 and 2013. Tumour types 
involved were breast, colorectal, lung, prostate, ovarian 
cancer and malignant melanoma. Centralised molecular 
testing of surplus material from resections or biopsies of 
primary/metastatic tissue was performed, with samples 
examined for 3–5 genetic alterations deemed to be of key 
interest in site-specific cancers by the National Cancer 
Research Institute Clinical Study groups.
Results 10 754 patients (98% of those approached) 
consented to participate, from which 7814 tumour 
samples were genetically analysed. In total, 53% had at 
least one genetic aberration detected. From 1885 patients 
with lung cancer, KRAS mutation was noted to be highly 
prevalent in adenocarcinoma (37%). In breast cancer 
(1873 patients), there was a striking contrast in TP53 
mutation incidence between patients with ductal cancer 
(27.3%) and lobular cancer (3.4%). Vast inter-tumour 
heterogeneity of colorectal cancer (1550 patients) was 
observed, including myriad double and triple combinations 
of genetic aberrations. Significant losses of important 
clinical information included smoking status in lung cancer 
and loss of distinction between low-grade and high-grade 
serous ovarian cancers.
Conclusion Nationwide molecular pathology testing 
in a non-trial setting is feasible. The experience with 
SMP1 has been used to inform ongoing CRUK flagship 
programmes such as the CRUK National Lung MATRIX trial 
and TRACERx.
Key questions
What is already known about this subject?
 ► The core genetics of the six cancers explored in this 
article are well delineated in projects such as The 
Cancer Genome Atlas.
What does this study add?
 ► Rather than being confined to one centre/city, this 
study looked at very high sample numbers (eg, 1885 
patients for lung cancer) across eight cities, offering 
a ‘snapshot’ of real-world somatic cancer genetics 
in the UK.
 ► By taking a reductionist rather than bioinformatic 
approach to genetic examination/analysis, we dis-
covered a number of striking results to validate.
 ► For example, the KRAS mutation rate was unexpect-
edly high in UK lung adenocarcinoma at 37%.
 ► In breast cancer, rates of TP53 mutation were 
nearly 10-fold higher in ductal versus lobular 
disease.
 ► The core genetics of rarer pathologies such as muci-
nous colorectal and tubular breast adenocarcinomas 
were also delineated.
How might this impact on clinical practice?
 ► This article and programme is intended as a reposi-
tory for advancing preclinical, translational and clin-
ical cancer research.
 ► Establishing the prevalence of core cancer genet-
ic alterations provides a platform to drive forward 
precision medicine and molecularly targeted clinical 
trials.
 ► We also convey the challenges of setting up a na-
tionwide infrastructure for molecular testing—an 
experience that we hope will be informative for other 
countries.
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IntRoduCtIon
The breadth of clinical and biological genomic chal-
lenges which have become apparent in cancer over the 
past five years highlights how technological advance is 
driving expectation ever higher. Knowledge of thera-
peutically targetable driver mutations in genes such as 
BRAF, EGFR and BRCA1/2 is now being supplemented 
by the discovery of a new generation of resistance muta-
tions: these include aberrations found in the same gene, 
for example, EGFR T790M, or in genes downstream of the 
same cellular pathway such as MEK-mediated resistance 
in BRAF-mutated melanoma.1–4
The Cancer Research UK Stratified Medicine 
Programme (SMP1) was established in response to 
growing demand for prospective analysis of prognostic 
and predictive genetic markers in clinical tumour 
samples.5 6 At inception, there were two systemic clinical 
deficits in the UK National Health Service (NHS) inhib-
iting progress towards molecular diagnostics as a compo-
nent of normal cancer care7:
1. A nationwide infrastructure facilitating key molecular 
pathology tests at the point of diagnosis was necessary. 
This would reduce waiting times involved with request-
ing a test in retrospect, expediting patient access to 
prognostic genetic information and associated genet-
ically targeted therapies.
2. Little infrastructure existed for the systematic genomic 
analysis of tumour tissue surplus to diagnostic require-
ments, whether obtained through biopsy or resection, 
in the majority of patients not recruited to clinical 
trials.8
The central aim of SMP1 was therefore to facilitate an 
experience and infrastructure for molecular diagnostics 
in solid cancers across the UK, establishing its incorpo-
ration in the normal pathway of patient care that could 
be further developed during subsequent phases of the 
programme (SMP2). We also hypothesised that, in an era 
where laboratory genomic studies are offering increasing 
degrees of complexity, ‘bridging’ studies such as SMP1 
would be necessary to ensure the ensuing data ‘storm’ 
runs in parallel with direct translational improvements 
in patient care.9 Perhaps as much progress could be 
gained by projects which focus on key genetic players and 
offer the opportunity to work backwards from identified 
patient responders.10–12
Here we offer a summary of important findings for 
implementation and clinical practice as well as core 
genetic results from patients across the UK in six disease 
areas: carcinomas of the breast, lung, colorectum, pros-
tate, ovary and malignant melanoma.
MetHods
the Cancer Research uK stratified Medicine Programme
The Cancer Research UK Stratified Medicine Programme 
(Research Ethics Committee reference 11/EE/0202) 
commenced in 2011, at clinical and laboratory sites in 
England, Wales and Scotland. Phase I (SMP1) took place 
between September 2011 and July 2013. Six different 
solid tumour types (breast, colorectal, lung, ovarian, 
prostate cancer and malignant melanoma) were chosen 
for study. Twenty-six participating hospitals formed the 
network, coordinated through Cancer Research UK and 
National Institute for Health Research-funded Experi-
mental Cancer Medicine Centres (grouped to form local 
‘Clinical Hubs’) (figure 1). At these sites, patient consent 
was sought for centralised molecular testing (performed 
at ‘Technology Hubs’) of surplus material from resec-
tions or biopsies of primary/metastatic tumour tissue, 
performed as part of routine clinical care.
The tumour types included in SMP1 were selected 
for their representation of a large percentage of the UK 
cancer demographic: breast, colorectal, lung and pros-
tate cancer make up over half of all incident cancer cases 
in the UK each year; ovarian cancer represents the fifth 
most common cancer in females; advanced malignant 
melanoma represents a clinically unmet need which has 
recently been successful as a driver for a new generation of 
genetically targeted therapies. Also, 3–5 genes of interest 
were prioritised for molecular testing in each tumour 
type, selected by relevant National Cancer Research Insti-
tute Clinical Study Groups for their prevalence and/or 
potential ‘actionability’. Samples were examined for the 
following gene alterations: PTEN, PIK3CA, BRAF and 
TP53 for breast and ovarian cancer; KRAS, EGFR, ALK, 
BRAF and DDR2 (squamous only) for lung cancer; KRAS, 
NRAS, BRAF, PIK3CA and TP53 for colorectal cancer 
(CRC); PTEN, BRAF and TMPRSS2-ERG for prostate 
cancer; BRAF, NRAS, PIK3CA and KIT for melanoma. 
Further information on the programme and techniques 
Figure 1 Participating sites for phase I of the Cancer 
Research Stratified Medicine Programme. Yellow markers 
represent clinical hubs, red markers represent clinical and 
technology hubs. ICR , Institute for Cancer Research; RBH, 
Royal Brompton Hospital; RMH , Royal Marsden Hospital.
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used for molecular analysis is detailed in online Supple-
mentary methods and supplementary methods table 1.
Patient eligibility
Eligibility criteria were designed to be broad and inclu-
sive in order to maximise the relevance of findings to 
the generalUK population. Patients had to be aged 18 
years or more, able to give written informed consent, 
and with a suspected or confirmed diagnosis of one of 
the following types of invasive malignancy: breast cancer 
(carcinoma including ductal, lobular and other subtypes); 
CRC (adenocarcinoma of the colon or rectum); lung 
cancer (carcinoma of the lung including both small cell 
and non-small cell subtypes but excluding carcinoid 
tumours and pleural malignant mesothelioma); malig-
nant melanoma (advanced stage III or IV disease with at 
least regional lymph node involvement, from cutaneous 
primaries as well as less common mucosal sites); ovarian 
cancer (adenocarcinoma) and prostate cancer (adeno-
carcinoma).
Analysis, interpretation and reporting
Patients consenting to participate in the programme were 
required to have a sample submitted of formalin-fixed 
paraffin-embedded tumour tissue from a resection or 
biopsy procedure with surplus tissue, beyond that needed 
for making a tissue diagnosis, taken either from the 
primary tumour or from a site of metastasis.
The SMP1 gene sets for each tumour type comprised 
well-characterised hotspots in oncogenes, structural 
chromosomal rearrangements, as well as screening of 
multiple exons in tumour suppressor genes such as PTEN 
and TP53. More information on this is available in online 
supplementary methods .
database analysis
For statistics, association of genotype with clinical char-
acteristics and patient demographics were assessed using 
Fisher’s exact test for dichotomous factors, and the Mann-
Whitney test for continuous data, which were not adjusted 
for multiple testing. All p values were two-sided and 
considered statistically significant at <0.05. More detail 
on database analysis, including data curation and compi-
lation, is available in online supplementary methods.
Results
Patient population
Between August 2011 and July 2013, 10 754 patients 
(98% of those approached) consented to participate in 
SMP1, with 9010 patient tumour samples examined. Of 
7814 samples with data available at the time of our anal-
yses, 53% had at least one aberration detected (table 1). 
Also, 44% of the samples were wild type for the genes and 
regions analysed and the remaining 3% of samples failed 
all gene tests. Data completeness varied between the clin-
ical sites and between data items (table 2).
lung cancer
Lung cancer samples were obtained from a total of 1885 
patients. The baseline demographics of these patients 
are shown in online supplementary table 1. In total, 774 
patients (41.1%) were diagnosed with adenocarcinoma, 
399 patients (21.2%) with squamous cell cancer and 
50 patients (2.6%) with small cell lung cancer. Also, 64 
patients (3.4%) were diagnosed with non-small cell lung 
cancer (NSCLC) of non-specific histological subtype 
(online supplementary figure 1). Due to the focus on 
resection samples where tissue was plentiful, the majority 
of samples collected represented stage I–II lung cancer 
(1006 samples, 53.4%), followed in frequency by stage III 
lung cancer (21%) then stage IV (19.4%) lung cancer. 
A substantial percentage of baseline information was 
returned as ‘not stated’ (ie, either not tested, not docu-
mented or both), the most important of which was a 
deficit of smoking history.
Figure 2A offers an overview of genetic results obtained 
from the lung adenocarcinoma population. Of those 
tested, 92/774 (11.9%) were EGFR mutant, 287/774 
(37.1%) were KRAS mutant, 19/774 (2.5%) were ALK 
rearranged and 18/774 were BRAF mutant (2.3%) 
(online supplementary table 2). The most common failed 
genetic test was KRAS, with no result returned in 127/774 
(16.4%) samples: incidence of gene mutation/modifica-
tion would have been considerably higher, particularly 
for KRAS (287/647 samples, 44.36%), had these failed 
samples been excluded from the total numbers in our 
final analysis (online supplementary table 3). A further 
breakdown of EGFR mutation results showed that 67/92 
(72.8%) EGFR-mutant cancers harboured a solitary sensi-
tising mutation, 10/92 (10.9%) a solitary resistance muta-
tion, 3/92 (3.3%) had both sensitising and resistance 
mutations and 12/92 (13%) had mutations of unknown 
significance (online supplementary table 4).
Table 1 Summary results of molecular analysis performed during SMP1 by tumour type
Tumour type
Breast 
cancer
Colorectal 
cancer Lung cancer
Malignant 
melanoma
Ovarian 
cancer
Prostate 
cancer
Number of samples 1873 1605 1885 535 557 1359
Failed all tests (%) 5.3 0.9 2.8 3.6 3.2 4.0
Wild type for all genes (%) 45 19 64 31 40 52
Aberration in more than one gene (%) 7 33 0.5 2 4 2
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In squamous cell carcinoma, DDR2 was mutated in 
12/175 (6.9%), an incidence that becomes substantially 
higher if the large numbers of failed tests are excluded 
from analysis (12/119 samples, 10.1%). EGFR mutations 
were present in 3/399 squamous samples (0.8%), while 
ALK rearrangement was present in 2/399 (0.5%). KRAS 
(12/399 samples, 3%) and BRAF (5/399 samples, 1.3%) 
mutations were present in small numbers (online supple-
mentary tables 2 and 3).
Forty-eight small cell lung cancers were analysed, with 
none of the samples harbouring a genetic mutation/
modification (online supplementary tables 2 and 3).
Breast cancer
In total, 1873 patients with breast cancer were analysed 
within SMP1 (online supplementary table 5). Also, 1423 
patients (76%) were diagnosed with invasive ductal carci-
noma (IDC), 179 patients (9.6%) with invasive lobular 
carcinoma (ILC), 25 patients (1.3%) with mucinous 
adenocarcinoma and 35 patients (1.9%) with tubular 
carcinoma. Sixty-seven patients (3.6%) were diagnosed 
with mixed IDC/ILC (online supplementary figure 2 
and table 6). Due to the focus on resection specimens, 
a majority of samples collected in SMP1 were taken 
from stage I–II breast cancer (1455 samples, 77.7%). Of 
patients where ER, PR and HER2 status was confirmed, ER 
was positive in 751/866 (86.7%) cancers, PR in 271/407 
(66.6%) cancers and HER2 in 142/807 (17.6%) cancers. 
Only 3.2% of patients were confirmed as ‘triple-negative’ 
(60/1873 with ER- PR- HER2-), perhaps reflecting the 
relatively low percentage of stage III–IV patients recruited. 
Again, a substantial percentage of baseline informa-
tion was returned as ‘not stated’, ranging from 35/1873 
(1.8%) of patients for histological subtype to 1466/1873 
(78.2%) of patients for PR status. ER and HER2 were not 
stated in 1007/1873 (53.8%) and 1066/1873 (56.9%) of 
patients, respectively.
On review of histopathological category, 420/1423 
(29.5%) of IDC samples were PIK3CA mutant, 65/1423 
(4.6%) were PTEN mutant, 389/1423 (27.3%) TP53 
mutant and none (0/1055 samples) were BRAF mutant 
(figure 2B and online supplementary table 6). The most 
common failed genetic test in IDC was PTEN, with no 
result returned in 354/1423 (24.9%) of samples tested: 
incidence of PTEN mutation would have increased to 
6.1% (65/1069 samples) had these failed samples been 
excluded in our final analysis (online supplementary 
table 7). Of ILC samples, PIK3CA was mutated in 60/179 
(33.5%), PTEN in 10/179 (5.6%), while TP53 mutation 
was present in 6/179 samples (3.4%). Also, 25 mucinous 
adenocarcinomas had PIK3CA mutation in 3/25 samples 
(12%), PTEN mutation in 0/25 samples and TP53 muta-
tion in 4/25 samples (16%), while 35 tubular adenocar-
cinomas displayed PIK3CA mutation in 17/35 samples 
Table 2 Overall SMP1 data completeness by patient disease cohort
Data item
Patient cohort
Overall
Breast 
cancer
Colorectal 
cancer
Lung 
cancer
Malignant 
melanoma
Ovarian 
cancer
Prostate 
cancer
Total number of patients 1873 1605 1885 535 557 1359 7814
Gender (%) 100 99 98 96 N/A N/A 98
Year of birth* (%) 100 100 100 100 100 100 100
Year of diagnosis (%) 79 75 52 74 67 69 69
Ethnic category (%) 71 73 75 81 70 60 72
Histological subtype (SNOMED 
morphology) (%) 
100 99 77 92 97 92 93
Histological grade† (%) 83 88 N/A N/A 62 53 72
Pathological T classification‡ (%) 92 69 91 33 35 50 62
Pathological N classification‡ (%) 86 81 89 31 24 35 58
Pathological M classification‡ (%) 24 74 77 54 79 33 57
Integrated TNM stage‡ (%) 92 89 94 71 84 55 81
For each data item, the percentage completeness given is the percentage of patient records containing valid and informative data according 
to the stipulated attributes in the clinical dataset.
*Date of birth and date of diagnosis were recorded at patient level but truncated to 'year of' as an information governance measure to 
maintain confidentiality.
†Not mandatory where this is not a core Royal College of Pathologists (RCPath) dataset reporting item. For prostate cancer, the percentage 
refers to overall completeness of Gleason score components requested in separate data items.
‡Alternative staging systems used as follows with completeness given in integrated stage field: FIGO for ovarian cancer, AJCC version of 
TNM7 for melanoma. TNM7 has been used in all cases apart from colorectal cancer where TNM5 is currently used in the UK according to 
RCPath guidance.
AJCC, American Joint Committee on Cancer; FIGO, International Federation of Gynaecology and Obstetrics; N/A, not available; SNOMED, 
Standard Nomenclature of Medicine; TNM5/7, l’Union Internationale Contre le Cancer (UICC) Tumour/Node/Metastasis Classification of 
Malignant Tumours 5th/7th edition. 
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(48.6%), PTEN mutation in 1/35 samples (2.9%) and 
TP53 mutation in 0/35 samples (online supplementary 
table 6 and 7).
Colorectal cancer
CRC samples were obtained from 1605 patients (online 
supplementary table 8). In total, 1508 patients (94%) 
were diagnosed with adenocarcinoma, with mucinous 
adenocarcinoma representing the most common histo-
logical variant (52/1605 samples, 3.2%). Also, 579 
samples (36.1%) represented TNM stage I–II CRC, 602 
samples (37.5%) stage III and 241 samples (15%) stage 
IV. The majority of tumours were graded as moderately 
differentiated (1126/1605, 70.2%). Again, a substantial 
percentage of baseline information was returned as ‘not 
stated’, ranging from 17/1605 (1.1%) of patients for 
histological subtype to 506/1605 (31.5%) of patients for 
lymphovascular invasion (‘LVI’, used as surrogate marker 
for extramural vascular invasion in core dataset).
The vast inter-tumour heterogeneity of CRC is clearly 
represented despite our analysis of only five genes, 
including myriad double and triple combinations of 
genetic aberrations (figure 2C). Of adenocarcinomas 
tested, 581/1508 (38.5%) were KRAS mutant, 824/1508 
(54.6%) were TP53 mutant, 144/1508 (9.5%) BRAF 
mutant, 61/1508 NRAS mutant (4%) and 158/1508 were 
PIK3CA mutant (10.5%) (online supplementary table 9). 
The most common failed genetic test was TP53, with no 
result returned in 291/1508 (19.3%) of samples tested, 
the incidence of this mutation would have increased to 
67.7% (824/1217 samples) had these failed samples been 
excluded from our final analysis (online supplementary 
table 10).
In CRC mucinous adenocarcinoma, BRAF was mutated 
in at least 20/52 (38.5%) of samples (online supplemen-
tary tables 9 and 10). Codon 600 BRAF V600E mutations 
accounted for 19 of the 20 samples from BRAF-mutated 
mucinous CRC. Incidence of BRAF mutation in mucinous 
CRC was significantly higher relative to its incidence in 
the SMP1 CRC adenocarcinoma population as a whole 
(p<0.0001). Of other genes tested, TP53 mutations were 
significantly less frequent (3/52 samples, 5.8%) relative 
to adenocarcinoma overall (p<0.0001), and PIK3CA 
mutations were more common (11/52 samples, 21.2%; 
p=0.022). NRAS and KRAS mutations were not signifi-
cantly different to that observed overall.
Prostate cancer
Samples from 1359 patients with prostate cancer were 
analysed (online supplementary table 11). Adenocarci-
noma histology was reported in 91.8% of cases diagnosed. 
In total, 430 cases (31.6%) were diagnosed at stages I–
II, 238 (17.5%) were stage III samples and 78 (5.7%) 
Figure 2 Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma 
(except mucinous subtype) (C), prostate cancer (D), ovarian cancer (E) and melanoma (F).
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were stage IV samples. 613 (45.2%) of samples were of 
unknown stage.
Figure 2D offers an overview of genetic results obtained 
from the prostate cancer population. In adenocar-
cinoma samples, 11/937 (1.2%) were BRAF mutant, 
67/1247 (5.4%) PTEN mutant and 501/1247 (40.2%) 
were TMPRSS2-rearranged. The most common failed 
genetic test in prostate cancer was PTEN, with no result 
returned in 303/1247 (24.3%) samples tested: incidence 
of gene mutation would have been higher, including for 
TMPRSS2-ERG (501/1117 samples, 44.9%), had these 
failed samples been excluded from our final analysis 
(online supplementary table 12).
ovarian cancer
Ovarian cancer samples were obtained from 557 women 
(online supplementary table 13). In total, 360 patients 
(64.3%) were diagnosed with serous carcinoma, 33 
patients (5.9%) with clear cell, 36 patients (6.5%) with 
endometrioid, 11 patients (2%) with mucinous and 72 
patients (12.9%) with unspecified epithelial ovarian 
cancer (EOC) (online supplementary table 12 and 
supplementary figure 3). The most common stage at 
presentation was stage III ovarian cancer (268 samples, 
48.1%), followed by stages I–II (117 samples, 21%), then 
stage IV (82 samples, 14.7%). A significant percentage of 
baseline information was returned as ‘not stated’, most 
importantly a deficit of information on low-grade versus 
high-grade disease.
Figure 2E gives an overview of ovarian cancer genetic 
results. Overall, 35/557 (6.3%) samples were PIK3CA 
mutant, 23/557 (4.1%) PTEN mutant, 265/557 (47.6%) 
TP53 mutant and 12/516 (2.3%) were BRAF mutant. In 
serous cancer, 6/360 (1.7%) were PIK3CA mutant, 2/360 
(0.6%) PTEN mutant, 181/360 (50.3%) TP53 mutant and 
7/327 (2.1%) were BRAF mutant (online supplementary 
table 14). The most common failed genetic test in serous 
EOC was PTEN, with no result returned in 114/360 
(31.7%) of samples tested: percentage mutation would 
have been 65.3% (181/277 samples) had these failed 
samples been excluded from our final analysis (online 
supplementary table 15).
For 33 clear cell EOCs, PIK3CA was mutated in nine 
samples (27.3%), PTEN mutation in four samples 
(12.1%), while TP53 mutation was present in seven 
samples (21.2%). In 36 endometrioid EOCs, PIK3CA was 
mutated in 9/36 samples (25%), PTEN mutation in 7/36 
samples (19.4%) and TP53 mutation in 12/36 samples 
(33.3%). Of 11 patients with mucinous EOC,TP53 muta-
tion was present in 5/11 mucinous samples (45.5%), 
with PI3KCA and PTEN mutations absent. BRAF mutation 
was absent in all subtypes except for serous EOC (online 
supplementary tables 14 and 15).
Metastatic melanoma
In total, 535 patients with metastatic melanoma were 
analysed (online supplementary table 16). A signifi-
cant percentage of baseline information was returned 
as ‘not stated’, ranging from 23/535 (4.3%) of patients 
for gender to 438/535 (81.9%) for LVI. 232/535 
patients (43.4%) were BRAF mutant, 124/535 (23.2%) 
NRAS mutant, 8/535 (1.5%) PIK3CA mutant and 7/535 
(1.3%) KIT mutant (Figure 2F). For BRAF mutation, 
219/232 samples were documented as ‘V600’ or ‘V600E’ 
(94.4%), with another 8/232 ‘V600K’ (3.4%). Removing 
gene test failures from the total number of samples, 
mutation prevalence in BRAF, NRAS, PIK3CA and KIT 
increased to 45.7%, 29.6%, 2% and 2.1%, respectively 
(online supplementary table 17).
dIsCussIon
Here we have reported results from the first UK-wide study 
assessing molecular pathways of cancer within the UK 
NHS. We focused on six common cancers (lung cancer, 
breast cancer, CRC, prostate cancer, ovarian cancer and 
metastatic melanoma), finishing with a 98% consent rate 
for patient participation. To the best of our knowledge, 
this study has offered a number of novel results relevant 
to our future understanding of UK cancer genetics that 
may also have international relevance. It also highlights a 
number of challenges which will be important for stream-
lining national molecular programmes in the future.
One key result from SMP1 was a 98% rate of patient 
consent for participation across all six cancer types. This 
success was achieved by the stipulation of a blood sample 
and ‘surplus’ tissue only for eligibility, that is, tissue derived 
from resection or biopsy, and remaining after all neces-
sary diagnostic tests had been performed. No additional 
invasive procedures were necessary, and results from clin-
ical trials that mandate further 'research protocol’ biop-
sies suggest that this percentage would have been lower 
had patients been asked to undergo this.13 This 98% 
acceptance rate also suggests that concerns about genetic 
and clinical data privacy are not as prevalent as might be 
expected, despite changing data protection regulations 
that have caused anxiety in the research community.14
Table 3 offers a perspective of the advantages and chal-
lenges involved with recruitment, data collection and anal-
ysis from SMP1. We believe these data offer a unique insight, 
unrepresented in other genomic studies: there was no 
planned selection bias, large patient numbers were involved 
and prospective assessment of important functional muta-
tions was implemented, demonstrating the feasibility of this 
programme to allow nationwide patient access to relevant 
novel therapies, clinical trials and other research oppor-
tunities. However, results were hypothesis-generating and 
should be interpreted within the context of a retrospective 
observational analysis requiring further clinical validation. 
Although selection bias may be minimised in a nationwide 
study such as this, the potential for unplanned bias still 
exists: for example, a concurrent clinical trial using SMP1 to 
select patients with a particular cancer genotype. Expected 
bias included a weighting towards specific histologies and 
early-stage disease, given the focus on submission of resected 
specimens to increase the likelihood of sufficient material 
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being available for analysis, and the possibility that we would 
be more likely to recruit patients not approached for other 
studies due to the concern of information overload in those 
already participating in other research. Significant losses of 
important clinical information included smoking status in 
lung cancer, ER/PR/HER2 status in breast cancer, tumour 
site in CRC and loss of distinction between low-grade and 
high-grade serous ovarian cancers. Since implementation 
of this study, the collection of detailed data on each cancer 
diagnosed has become more established in the UK with 
the widespread adoption of the Cancer Outcomes Services 
Dataset (COSD). It is imperative that cancer treatment 
centres collect the key data elements within COSD which 
could support studies like SMP1 in the future.
SMP1 served as the basis for inception and imple-
mentation of the current second phase, SMP2, which 
provides patients access to molecular pre-screening of 
surplus diagnostic lung cancer biopsy or cytology cell 
block samples to inform entry to the National Lung 
Matrix Trial (NLMT).11 The NLMT directly incorpo-
rates many aspects of the SMP1 infrastructure, this time 
facilitating multi-arm, molecularly stratified clinical trial 
design for patients with advanced stage non-small cell 
lung cancer (NSCLC). Its key aim is to demonstrate the 
Table 3 Summary of advantages and challenges encountered in SMP1
Advantages Challenges 
Recruitment Broad patient eligibility, determined by histological diagnosis 
of one of the six cancers types, enabling inclusion of a range 
of patients from across the UK, all receiving care within the 
National Health Service (NHS)
Approval granted by research ethics committee for clinical 
sites to use existing biobanking consent forms and 
information sheets, after review to confirm equivalence with 
CRUK SMP1 paperwork
Potential for unplanned selection biases 
impacting SMP1 patient recruitment due to 
concurrent clinical trials, for example, for 
patients with oestrogen receptor-positive breast 
cancer
Sample 
preparation 
and analysis
Insights generated into differences in tissue handling 
processes between different laboratories, facilitating the 
process of harmonising practice and understanding the 
impact on subsequent genetic analysis
Collaborative working between technology hubs facilitating 
shared learning and evidence-based evolution of approach to 
genetic analysis and variant interpretation
Move away from single gene tests using diverse techniques 
to multiplex panel-based next-generation sequence analysis 
during SMP1
Ability to adapt technology throughout SMP1 in order to 
incorporate additional genetic markers (eg, extended scope of 
BRAF, addition of DDR2) for specific add-on studies
Test failures due to variation in performance 
of and variations in tissue sample quality 
increased workload and time taken for analysis
Achieving delivery of clinically relevant 
turnaround times proved challenging during 
SMP1
Data 
collection
Dataset drawn from existing information standards (such as 
the Cancer Outcomes and Services Dataset) with data item 
definitions according to the NHS Data Dictionary
Electronic test request/report system established between 
clinical and laboratory sites, minimising duplication of data 
entry and risk of transcription errors
Nationwide/cross-border network for data registration and 
submission established
Excessive number of data items in SMP1 
dataset and focus on core rather than tumour-
type-specific data items led to loss or omission 
of important information such as smoking 
history and performance status
Lack of unified electronic patient record as 
single source of individual data items increased 
workload for sites
Data analysis Large patient numbers allowing in-depth analysis for particular 
genetic aberrations, such as
 ► Relationship to clinical staging and demographics
 ► Relationship to other genetic modifications
 ► Paired samples taken from the same patient
Hypothesis-generating for ongoing research
No multivariate survival analysis
Benefits to 
participating 
patients and 
staff
Upfront genetic diagnosis of tumour samples enabling 
potential access to new therapies, trials and translational 
research including National Lung Matrix Trial through SMP2 
pre-screening
Increased awareness of role of somatic mutation analysis in 
cancer care
Creation of a collaborative, multidisciplinary knowledge 
network for stratified medicine
Generation of genetic data of unknown 
significance, for which no known treatment or 
trial-based approaches are available
NLMT, National Lung Matrix Trial.
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feasibility of combining molecular testing with clinical 
trial enrolment and translational progress on a national 
level, with its advances reported in tandem with other 
pioneering Cancer Research UK translational and clin-
ical trial programmes such as TRACERx, DARWIN and 
PEACE.15–17
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